AFP and neoplasm: To illustrate the differential risk, the risk of waitlist dropout for a patient with compensated liver disease (INR 1.0, bilirubin 1.0 mg/dl, no ascites), AFP 100 ng/ml, and a single 3.0 cm tumor would have a low calculated dropout risk of 4% at 3 months, 8% at 3 months, and 18% at 12 months.